Rockwell Med (RMTI)
In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Rockwell Med, with a price target of $3.00. The company’s shares closed last Friday at $0.47, close to its 52-week low of $0.34.
According to TipRanks.com, Selvaraju has 0 stars on 0-5 stars ranking scale with an average return of
Rockwell Med has an analyst consensus of Moderate Buy, with a price target consensus of $3.00.
In a report released today, Andrew Fein from H.C. Wainwright maintained a Buy rating on Biogen, with a price target of $270.00. The company’s shares closed last Friday at $239.30, close to its 52-week low of $217.10.
According to TipRanks.com, Fein is a 3-star analyst with an average return of
Currently, the analyst consensus on Biogen is a Moderate Buy with an average price target of $290.00, a 23.4% upside from current levels. In a report issued on January 7, Truist Financial also maintained a Buy rating on the stock with a $343.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on RMTI:
- Shopify vs. Wix.com: Which E-commerce Platform Is Poised for Growth?
- AUTO1 Group SE (ATOGF) Receives a Hold from J.P. Morgan
- Needham Thinks AdTheorent Holding’s Stock is Going to Recover
- Ford Hires Stripe to Boost its E-commerce Plans
- Analysts Are Bullish on Top Healthcare Stocks: SAGE Therapeutics (SAGE), Glaukos (GKOS)